|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
|---|---|
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00661661 |
Purpose
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are only eligible for this study after they have completed participation in another "qualifying" study of CP-690,550.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis |
Drug: CP-690,550 |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Long-Term, Open-Label Study Of CP-690,550 To Confirm The Safety Following Long Term Administration Of CP-690,550 In The Treatment Of Rheumatoid Arthritis |
| Estimated Enrollment: | 240 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| CP-690,550, 1 mg: Experimental |
Drug: CP-690,550
5 mg BID, 5 tablets administered BID for 2 years.
|
Eligibility| Ages Eligible for Study: | 20 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
| Japan | |
| Pfizer Investigational Site | Recruiting |
| Chiba, Japan | |
| Pfizer Investigational Site | Recruiting |
| Fukuoka, Japan | |
| Pfizer Investigational Site | Recruiting |
| Niigata, Japan | |
| Japan, Fukuoka | |
| Pfizer Investigational Site | Recruiting |
| Kitakyusyu, Fukuoka, Japan | |
| Japan, Ibaraki | |
| Pfizer Investigational Site | Recruiting |
| Hitachi-shi, Ibaraki, Japan | |
| Japan, Kanagawa | |
| Pfizer Investigational Site | Recruiting |
| Sagamihara, Kanagawa, Japan | |
| Japan, Kumamoto | |
| Pfizer Investigational Site | Recruiting |
| Koushi, Kumamoto, Japan | |
| Japan, Miyagi | |
| Pfizer Investigational Site | Recruiting |
| Sendai, Miyagi, Japan | |
| Japan, Osaka | |
| Pfizer Investigational Site | Recruiting |
| Kawachinagano, Osaka, Japan | |
| Japan, Saitama | |
| Pfizer Investigational Site | Recruiting |
| Kawagoe-shi, Saitama, Japan | |
| Pfizer Investigational Site | Recruiting |
| Kitamoto, Saitama, Japan | |
| Japan, Tokyo | |
| Pfizer Investigational Site | Recruiting |
| Bunkyo-ku, Tokyo, Japan | |
| Pfizer Investigational Site | Recruiting |
| Shinjyuku-ku, Tokyo, Japan | |
| Pfizer Investigational Site | Recruiting |
| Chiyoda-ku, Tokyo, Japan | |
| Pfizer Investigational Site | Recruiting |
| Koto-ku, Tokyo, Japan | |
| Pfizer Investigational Site | Recruiting |
| Meguro-ku, Tokyo, Japan | |
| Pfizer Investigational Site | Recruiting |
| Musashimurayama-shi, Tokyo, Japan | |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
| Responsible Party: | Pfizer ( Director, Clinical Trial Disclosure Group ) |
| Study ID Numbers: | A3921041 |
| Study First Received: | February 7, 2008 |
| Last Updated: | January 5, 2009 |
| ClinicalTrials.gov Identifier: | NCT00661661 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
|
Long term open label study in Japan |
|
Autoimmune Diseases Musculoskeletal Diseases Joint Diseases Arthritis |
Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases |
|
Immune System Diseases |
